GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Access Bio Inc (XKRX:950130) » Definitions » Cyclically Adjusted PB Ratio

Access Bio (XKRX:950130) Cyclically Adjusted PB Ratio : 0.91 (As of Sep. 21, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Access Bio Cyclically Adjusted PB Ratio?

As of today (2024-09-21), Access Bio's current share price is ₩6340.00. Access Bio's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 was ₩6,978.19. Access Bio's Cyclically Adjusted PB Ratio for today is 0.91.

The historical rank and industry rank for Access Bio's Cyclically Adjusted PB Ratio or its related term are showing as below:

XKRX:950130' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.91   Med: 1.9   Max: 6.16
Current: 0.91

During the past years, Access Bio's highest Cyclically Adjusted PB Ratio was 6.16. The lowest was 0.91. And the median was 1.90.

XKRX:950130's Cyclically Adjusted PB Ratio is ranked better than
73.17% of 123 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.05 vs XKRX:950130: 0.91

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Access Bio's adjusted book value per share data for the three months ended in Jun. 2024 was ₩18,347.993. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ₩6,978.19 for the trailing ten years ended in Jun. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Access Bio Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Access Bio's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Access Bio Cyclically Adjusted PB Ratio Chart

Access Bio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 2.79 1.48

Access Bio Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.51 2.12 1.48 1.14 0.95

Competitive Comparison of Access Bio's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, Access Bio's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Access Bio's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Access Bio's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Access Bio's Cyclically Adjusted PB Ratio falls into.



Access Bio Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Access Bio's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=6340.00/6978.19
=0.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Access Bio's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Access Bio's adjusted Book Value per Share data for the three months ended in Jun. 2024 was:

Adj_Book=Book Value per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=18347.993/132.5538*132.5538
=18,347.993

Current CPI (Jun. 2024) = 132.5538.

Access Bio Quarterly Data

Book Value per Share CPI Adj_Book
201409 2,176.880 100.428 2,873.245
201412 2,241.297 99.070 2,998.822
201503 2,210.822 99.621 2,941.675
201506 2,263.778 100.684 2,980.341
201509 2,395.519 100.392 3,162.968
201512 2,380.958 99.792 3,162.616
201603 2,382.916 100.470 3,143.857
201606 2,429.127 101.688 3,166.447
201609 2,331.473 101.861 3,033.993
201612 2,186.377 101.863 2,845.130
201703 2,034.462 102.862 2,621.718
201706 2,018.249 103.349 2,588.572
201709 1,960.181 104.136 2,495.107
201712 1,676.615 104.011 2,136.711
201803 1,638.320 105.290 2,062.556
201806 1,573.296 106.317 1,961.556
201809 1,524.122 106.507 1,896.859
201812 1,421.892 105.998 1,778.122
201903 1,384.345 107.251 1,710.950
201906 1,299.060 108.070 1,593.376
201909 1,147.970 108.329 1,404.677
201912 749.179 108.420 915.942
202003 756.546 108.902 920.860
202006 756.394 108.767 921.811
202009 1,208.322 109.815 1,458.524
202012 2,351.586 109.897 2,836.403
202103 5,935.213 111.754 7,039.857
202106 5,309.641 114.631 6,139.793
202109 6,103.912 115.734 6,990.985
202112 8,049.821 117.630 9,071.146
202203 16,164.055 121.301 17,663.555
202206 19,224.782 125.017 20,383.804
202209 20,669.267 125.227 21,878.675
202212 18,199.029 125.222 19,264.620
202303 19,032.403 127.348 19,810.451
202306 18,101.777 128.729 18,639.661
202309 18,197.503 129.860 18,575.061
202312 17,276.615 129.419 17,695.036
202403 17,908.502 131.776 18,014.179
202406 18,347.993 132.554 18,347.993

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Access Bio  (XKRX:950130) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Access Bio Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Access Bio's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Access Bio Business Description

Traded in Other Exchanges
N/A
Address
65 Clyde Road, Suite A, Somerset, NJ, USA, 08873
Access Bio Inc is a United States based bio company engaged in the research, development, and manufacturing of in vitro rapid diagnostic tests, biosensor, and molecular diagnostic products. The products are for the prevention and early diagnosis of infectious diseases. The company's core in vitro-diagnostic technology includes immunochemical, biochemical and molecular products. The company offers products for Rapid Diagnostic Tests including CareStart G6PD RDT, CareStart Malaria, CareStart Dengue Combo, and CareStart Scrub Typhus IgM; Biosensors product includes CareStart G6PD Biosensor, and Molecular Diagnostics products include CareStart HPV and CareStart CAH.

Access Bio Headlines

No Headlines